COMPLETENESS OF REAL-WORLD DATA (RWD) IN CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY (CAR-T) FOR RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN UNITED STATES (US) COMMUNITY ONCOLOGY/HEMATOLOGY PRACTICES (CH/OS)

CAR-T can be dramatically effective for some patients with R/R DLBCL. Currently, however, access has been limited to major academic centers. Moreover, many patients who could benefit from CAR-T may not have appropriate access or receive timely referral. To broaden access, CAR-T may become available in the cH/O setting, from which RWD describing the treatment journey are lacking. To explore feasibility of c/HO-administered CAR-T and identify critical deficiencies, we assessed completeness of and cH/O access to patient CAR-T outcomes data. A retrospective, observational, multicenter chart review was conducted of 65 adults with R/R DLBCL referred by 13 US cH/Os and receiving CAR-T in 2019. The referring cH/Os abstracted relevant clinical decision-making data (events and dates), which were assessed for completeness. Initial and R/R DLBCL diagnoses and dates were reported for 100% of patients (N=65), and 100% of the 23 patients who relapsed post-CAR-T had relapse dates available. All patients had regimens and dates of first-line therapy initiation. Data availability for lymphodepletion was 100%. Proportions of patients having specific events surrounding CAR-T were reported for referral (100%), leukapheresis (43%), and first cH/O visit post-CAR-T (100% unless not occurred). 21 patients (32%) underwent allogeneic stem cell transplantation (ASCT). 24 patients (37%) were hospitalized post-CAR-T (setting reported for 55%), median length of stay was 18 days, and 5% of patients had emergency visits. Access to RWD describing episodes of care for CAR-T in cH/O practice can be instrumental in understanding CAR-T across diverse patient populations and lay the groundwork for considering administration in a community setting. Timely, agile data resources for clinical decision-making will be needed to ensure optimal outcomes in this setting. Universal methods ensuring access to appropriate data collection, management, and assessment by cH/Os will speed dissemination of this novel therapy beyond major academic centers.